An androgen receptor N-terminal domain antagonist for treating prostate cancer

Hormone therapies for advanced prostate cancer target the androgen receptor (AR) ligand-binding domain (LBD), but these ultimately fail and the disease progresses to lethal castration-resistant prostate cancer (CRPC). The mechanisms that drive CRPC are incompletely understood, but may involve consti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Myung, Jae-Kyung, Banuelos, Carmen A., Fernandez, Javier Garcia, Mawji, Nasrin R., Wang, Jun, Tien, Amy H., Yang, Yu Chi, Tavakoli, Iran, Haile, Simon, Watt, Kate, McEwan, Iain J., Plymate, Stephen, Andersen, Raymond J., Sadar, Marianne D.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2013
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3696543/
https://ncbi.nlm.nih.gov/pubmed/23722902
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI66398
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados